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Naturally occurring molecules derived from higher plants, animals, microorganisms and minerals play an important role in the 
discovery and development of novel therapeutic agents. The identification of molecular targets is of interest to elucidate the 
mode of action of these compounds, and it may be employed to set up target-based assays and allow structure-activity rela-
tionship studies to guide medicinal chemistry efforts toward lead optimization. In recent years, plant-derived natural com-
pounds possessing potential anti-tumor activities have been garnering much interest and efforts are underway to identify their 
molecular targets. Here, we attempt to summarize the discoveries of several natural compounds with activities against hemato-
logical malignancies, such as adenanthin, oridonin, gambogic acid and wogonoside, the identification of their targets, and their 
modes of actions. 
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The use of bioactive small molecules, either as single mo-
lecular entities or as mixtures, for treating disease is an in-
tegral part of human medicine [1,2]. Actually, the great res-
ervoir of natural compounds derived from higher plants, 
animals, microorganisms and minerals demonstrate their 
important role in the discovery and development of novel 
therapeutic drugs [3,4]. According to a detailed analysis of 
new medicines approved by the US Food and Drug Admin-
istration (FDA) between 1981 and 2010, about 34% of these 
medicines based on small molecules were natural products 
or direct derivatives of natural products [5]. However, while 
there is an enormous diversity in the number of plant spe-
cies (besides animals, microorganisms and minerals) 
worldwide, less than 10% have been screened for biological 
activity, and only 15% have been phytochemically evaluat-
ed. Information concerning the mechanisms of action of 
bioactive natural products at a molecular level, especially 
the molecular target(s) of a drug candidate, is of great sig-
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nificance, since it could help set up target-based assays and 
allow structure-activity relationship studies to guide medic-
inal chemistry efforts toward lead optimization [1,6]. How-
ever, achieving this in an effective, unbiased, and efficient 
manner is a significant challenge in this new era of drug 
discovery and optimization [7–9]. 
Hematological malignancies such as leukemia, lympho-
mas, and multiple myelomas are a large class of diseases 
that are characterized by the uncontrolled malignant prolif-
eration, blockade of differentiation and inhibited apoptosis 
of blood cells [10]. Some of their prominent features in-
clude rapid progression and evasion to treatment, thus lead-
ing to resistance and relapse. In past decades, rapid devel-
opment of molecular targeted therapy has been best illus-
trated by advances in the management of hematological 
malignancies [11]. For example, several generations of ty-
rosine kinase inhibitors including imatinib, dasatinib, ni-
lotinib, as well as ponatinib and bosutinib have had a tre-
mendous impact on the clinical outcomes of chronic mye-
loid leukemia (CML). These compounds act by selectively 
inhibiting the oncogenic breakpoint cluster region-Abelson 
(BCR-ABL) fusion protein [12], found in CML cells carry-
ing the chromosome translocation t(9;22) (q34;11), known 
as the Philadelphia chromosome, which causes fusion be-
tween the BCR and the ABL genes resulting in the expres-
sion of the potent kinase activity by the BCR-ABL fusion 
protein [13–15].  
As summarized by Meng and Huang [16] in this issue, 
Chinese scientists and physicians have also made great con-
tributions to the fight against hematological malignancies, 
especially leukemia. A typical example is the effective ap-
plications of all-trans retinoic acid (ATRA, a vitamin A 
derivative) and arsenic trioxide (an ancient drug used in 
traditional Chinese medicine) in acute promyelocytic leu-
kemia (APL, a subtype of acute myeloid leukemia (AML)), 
majority of which carry a chromosome translocation t(15;17) 
expressing the oncogenic promyelocytic leukemia retinoic 
acid receptor-alpha (PML-RAR) fusion protein [17]. Both 
drugs cleave or degrade the fusion protein, where arsenic 
trioxide was shown to bind directly to cysteine residues in 
zinc fingers located within the RBCC domain of PML- 
RAR and PML, inducing PML oligomerization and thus 
enhancing sumoylation and degradation of these two pro-
teins [18]. On the other hand, ATRA selectively inhibits and 
degrades the active unique peptidyl-prolyl-isomerase Pin1 
in cancer cells by directly binding to substrate phosphate- 
and proline-binding pockets in its active site, and thereby 
degrading degrades the oncogenic PML-RAR fusion pro-
tein [19].  
Thalidomide, which was developed and sold as a seda-
tive around 60 years ago but was soon banned because of its 
association with serious developmental defects, is being 
re-evaluated and is recognized as an effective treatment for 
myeloma [20,21]. Thalidomide derivatives including le-
nalidomide and pomalidomide have also been developed. 
More recently, thalidomide and its derivatives have been 
shown to directly target the cereblon (CRBN) protein, a 
substrate-recognition component of an ubiquitin E3 ligase 
enzyme complex, promoting the degradation of the tran-
scription factors Ikaros (IKZF1) and Aiolos (IKZF3), un-
derlying the drugs’ efficacy against myeloma [22,23]. Le-
nalidomide was also shown to be a highly effective treat-
ment option for myelodysplastic syndrome (MDS) with 
deletions of chromosome 5q [24,25], a disorder of hemato-
poietic stem cells. Recently, Krönke et al. [26] reported that 
lenalidomide targets the CRBN protein to induce ubiquiti-
nation and degradation of casein kinase 1A1, which is en-
coded by a gene within the common deleted region in 
del(5q) MDS, providing a mechanistic basis for the thera-
peutic window of lenalidomide in del(5q) MDS. 
Inspired by these successful practices, many natural com-
pounds were evaluated for their potential activities against 
hematological malignancies in the past decades [27,28]. Here 
we attempt to focus on several natural products that have 
shown anti-hematological malignancy activity and the iden-
tification of their potential targets.  
1  Adenanthin  
Diterpenoids, a large class of secondary metabolites isolated 
from plants, possess a wide spectrum of biological activities 
such as anti-tumor, anti-inflammation and significant car-
diovascular effects [29,30]. Structurally, they can be classi-
fied into four groups including the ent-kauranes, ent-6,7- 
secokauranes, ent-8,9-secokauranes and others (for more 
detail, see reference [30]). More than 600 diterpenoids have 
been identified in China thus far, some of these are abun-
dant in plants such as Isodon (Rabdosia). Through our co-
operation with professor Hang-Dong Sun’s group in the 
State Key Laboratory of Phytochemistry and Plant Re-
sources in West China, Kunming Institute of Botany, Chi-
nese Academy of Sciences, we screened up to 400 natural 
ent-kaurene diterpenoids [31] for their potential anti- 
leukemic activities. We demonstrated that pharicin B, a 
natural ent-kaurane diterpenoid from the leaves of Isodon 
pharicus (a type of Chinese herbal plant found mainly in 
Tibet), can rapidly stabilize and enhance ATRA-dependent 
transcriptional activity of the RAR protein, through which 
the natural product exhibits a synergistic or additive differ-
entiation-enhancing effect with ATRA in several AML cell 
lines and some primary leukemic cells [32]. We also re-
ported that pharicin A (Figure 1B), another ent-kaurene 
diterpenoid originally extracted from Isodon pharicus 
leaves, directly binds to BubR1 to induce mitotic arrest in 
leukemia and solid tumor-derived cells including chemo-
therapeutic drug paclitaxel-resistant malignant cells, and 
cells with unaligned chromosomes, aberrant BubR1 locali-
zation and deregulated spindle checkpoint activation [33]. 
Here we focus on the anti-leukemic activity of adenanthin  
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and the identification of its targets. Adenanthin (Figure 1),  
a diterpenoid isolated from the leaves of Rabdosia adenan-
tha [34], significantly decreases cell viability at a concen-
tration of more than 4 mol L1, while it also induces APL 
cells to undergo differentiation, independent of their sensi-
tivity to ATRA [35]. Our further investigations showed that 
the adenanthin-induced differentiation can also be seen in 
primary leukemic blasts from the bone marrow of APL pa-
tients and in four of six newly diagnosed non-APL AML 
patients [36], suggesting that its differentiation-inducing 
effect is not restricted to APL. Applying isogenic B strain of 
Friend leukemia Virus (FVB/N) mice models with intrave-
nous transplantation of ATRA-sensitive and ATRA- re-
sistant leukemic blasts from transgenic mice expressing 
human PML-RAR and its mutated form, we revealed that 
the intravenous administration of adenanthin (5 mg kg1 
body weight, each day for five consecutive days a week) 
significantly induces differentiation and tumor regression, 
and prolongs the survival of these two kinds of leukemic 
mice in spite of their sensitivity to ATRA [35]. Further-
more, adenanthin also significantly eliminates APL-initiat- 
ing progenitor cells (CD34+, c-kit+, FcRIII/II+, and Gr1int) 
in ATRA-sensitive leukemic mice [35]. All these results 
point to the potential therapeutic efficacy of adenanthin 
against AML.  
Thus, we attempted to identify the potential target(s) for 
adenanthin’s differentiation-inducing effect via a chemical 
proteomic approach [35,36], similar to that summarized by 
Ziegler et al. [6]. For this purpose, a biotin-tagged adenan-
thin probe, which retained the ability to induce leukemic 
cell differentiation, was synthesized after establishing the 
structure-activity relationships of adenanthin. It was as-
sumed that the ,-unsaturated moiety in adenanthin is a 
Michael acceptor that potentially captures nucleophiles such 
as cysteine (Cys) at its targeted binding site and forms co-
valent adducts, thus allowing for efficient protein recovery 
by the pull-down probe. Actually, reduction of the Michael 
acceptor double bond of adenanthin to a single bond abol-
ished its in vitro and in vivo differentiation-inducing activity 
in leukemic cells (Figure 1), making it a suitable negative 
control. Thus, the NB4 APL cell line lysates were incubated 
with biotin-tagged adenanthin or free biotin, and the bound 
proteins were isolated with streptavidin-coated agarose 
beads, followed by sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis and silver staining. The biotin-tagged 
adenanthin clearly precipitated only one detectable band at   
 
 
Figure 1  Structural formula of adenanthin and adenanthin-based pulldown probes as well as identification of its targets and molecular mechanism [6,35,36]. 
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approximately 23 kD (Figure 1), which was completely 
inhibited by high concentrations of unlabeled adenanthin, 
indicating a specific interaction. Mass spectrometry re-
vealed that the adenanthin-bound protein is peroxiredoxin I 
and II (Prx I–II) [35].  
Prxs, a family of small non-seleno peroxidases that cat-
alyze peroxide reduction of reactive oxygen species (ROS, 
the most significant of which is hydrogen peroxide ), have 
drawn much interest because of their role as second mes-
sengers in cellular signaling pathways [37,38]. They have a 
conserved Cys residue (the peroxidatic Cys, CP) that serves 
as the site of oxidation by peroxides. Peroxides oxidize the 
CP-SH to CP-SOH, which reacts with another Cys residue 
typically named resolving Cys (CR) to form a disulfide that 
is subsequently reduced by an appropriate electron donor. 
According to the location or absence of the CR, the mam-
malian Prxs include 2-Cys (Prx I-IV), atypical 2-Cys (Prx 
V), and 1-Cys Prx (Prx VI) subfamilies [39]. Thus, we 
further blotted the precipitates with antibodies against all 
these six Prxs, all of which were expressed in NB4 cells, 
and demonstrated that biotin-tagged adenanthin pulled 
down cellular Prx I and II but not Prx IV-VI. Adenanthin 
also effectively bound to the in vitro recombinant Prx I and 
II proteins, an interaction that was competitively inhibited 
at high concentrations of unlabeled adenanthin but not by 
the negative control compound mentioned above. Moreo-
ver, biotin-tagged adenanthin co-localized with Prx I and II 
in the cytoplasm and nuclei of NB4 cells. Further investi-
gations of mass spectrum-fragmentation patterns revealed 
selectivity for the Cys residues modified in Prx I and II, 
that is, the conserved CR of Prx I (Cys
173) or II protein 
(Cys172) is the specific binding site for adenanthin. It re-
mains to be investigated how adenanthin selectively binds 
to the specific Cys residues. Such a selective Cys binding 
action was recently reported for other natural compounds. 
For instance, a complex natural product ainsliadimer     
A selectively binds to the conserved Cys46 residue of   
IB kinase /, leading to the inhibition of both canonical 
and non-canonical nuclear factor kappa-B (NF-B) path-
ways [40]. 
Following binding to Prx I and II, adenanthin effective-
ly inhibits the peroxidase activity of the recombinant Prx 
I/II protein. Accordingly, adenanthin treatment induced a 
moderate increase in intracellular H2O2 level. The concept 
has been proposed that modulation of the abundance of 
H2O2 is critical in regulating the balance between 
self-renewal and differentiation of hematopoietic stem 
cells [41]. Indeed, pre-treatment with N-acetyl-l-cysteine, 
which effectively inhibits adenanthin-induced H2O2 accu-
mulation, completely abrogated adenanthin-induced 
growth arrest and differentiation of APL cells. Our results 
further propose that the adenanthin-elevated H2O2 levels 
activate extracellular signal-regulated kinase (ERK) 1/2 
and subsequently leads to increased transcription of 
CCAAT/enhancer binding protein beta, which has been 
proven to induce differentiation of immature cells to gran-
ulocytes and monocytes (Figure 1). 
Notably, we also showed that the Prx I protein is essen-
tial for the survival of hepatocellular carcinoma cells, and 
that adenanthin can kill these malignant liver cells in vitro 
and in xenografts by targeting Prx I/II [42]. However, the 
possibility could not be excluded that adenanthin might 
also bind with other protein(s). Actually, we showed that 
adenanthin exerts effective preventive and therapeutic ef-
fects on experimental autoimmune encephalomyelitis, 
which might be mediated via its inhibitory action on 
NF-B signaling pathway [43]. More recently, it was also 
shown that, next to Prx I/II, adenanthin also targets and 
inhibits the activity of additional proteins including     
the thioredoxin-thioredoxin reductase (TrxR) system and 
protein disulfide isomerase [44], as well as glutathione 
(GSH) [45]. However, Siernicka et al. [46] recently report 
that adenanthin only slightly reduces the total GSH in nat-
ural killer (NK) cells, which are considered critical com-
ponents of the innate and adaptive immune responses as 
reviewed in this issue [47]. In the Siernicka et al.’s [46] 
report, they also show that adenanthin induces intracellular 
oxidative stress in human NK cells, with greater effects 
towards Prxs-related antioxidants rather than GSH-related 
defences. In spite of this, the interactions between adenan-
thin and Prx are crucial for proposing Prx as a therapeutic 
target for cancer [38]. Adenanthin and the recently identi-
fied Prxs-targeting compound theonellasterone [48], a ste-
roidal metabolite isolated from a Theonella sponge, war-
rant further investigation for their anti-leukemia and   
anti-cancer activity. 
2  Oridonin 
Oridonin is also a natural ent-kaurane diterpenoid which 
was isolated in the 1970s from the Isodon plant Rabdosia 
rubescens (Donglingcao named in Chinese), a Chinese 
traditional medicinal herb commonly used for the treat-
ment of sore throat, inflammation, and gastrointestinal 
problems in central China [49,50]. A series of in vitro 
studies showed that oridonin can inhibit the proliferation 
and/or induce apoptosis of cancer cells of various origins 
such as prostate cancer, breast cancer, non-small cell lung 
cancer, glioblastoma and human melanoma [51–54]. The 
cytokinetic effects of oridonin on murine leukemia cells 
were reported in the middle of the 1980s, furthering our 
understanding of its properties [55,56]. For the past ten 
years, the anti-leukemic effects of oridonin have been at-
tracting greater interest. Zhou et al. [57] reported that 
oridonin induces apoptosis of AML cells carrying the 
chromosome translocation t(8;21), which expresses the 
AML1-ETO fusion protein, and prolongs the lifespan of 
C57 mice bearing AML1-ETO-expressing leukemic cells. 
It also inhibits tumor growth in nude mice inoculated with 
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t(8;21)-harboring leukemic Kasumi-1 cells. They further 
demonstrated that oridonin cleaves AML1-ETO to a cata-
bolic fragment, which can be blocked by pre-incubation 
with caspase inhibitors, and that the ectopic expression of 
AML1-ETO enhances the apoptotic effect of oridonin in 
the non-AML1-ETO-carrying AML cell line U937. 
Mechanistically, oridonin interacts with glutathione and 
TrxR to increase intracellular ROS, which in turn activates 
caspase-3 in t(8;21)-carrying AML cells. In addition, 
oridonin binds to the Cys347 of AML1-ETO, directing en-
zymatic cleavage at its aspartic acid 188 via caspase-3 to 
generate a truncated AML1-ETO (∆AML1-ETO) and pre-
venting the protein from further proteolysis. The 
∆AML1-ETO interacts with AML1-ETO and interferes 
with the trans-regulatory functions of the remaining 
AML1-ETO oncoprotein, thus acting as a tumor suppres-
sor that mediates the anti-leukemia effect of oridonin [58]. 
These results show that oridonin is a potential lead com-
pound for molecular target-based therapy of leukemia.  
The anti-leukemic effects of oridonin do not appear to 
be restricted to t(8;21)-carrying AML cells. Actually, 
oridonin has also been shown to enhance leukemia cell 
differentiation or induce cell death in several other types of 
AML cells. Oridonin was also shown to kill some lym-
phoid malignancies, including multiple myeloma, adult 
T-cell leukemia and non-Hodgkin’s lymphoma (NHL), 
possibly mediated by inhibition of the DNA-binding activ-
ity of NF-B [59]. The natural compound also dose-   
dependently induced apoptosis of the OCI-AML3 cell line 
harboring nucleophosmin (NPM) 1 mutations [60]. This is 
the most common genetic lesion in adult AML patients, 
accounting for 60% of cases with a normal karyotype and 
causes the skewed cytoplasmic accumulation of the NPM 
mutant protein (NPM1c+), which is thought to be responsi-
ble for leukemia pathogenesis. The oridonin-induced 
apoptosis is accompanied by activation of caspase-3 and 
nuclear translocation of the NPM1c+ protein [60]. Howev-
er, the direct target of oridonin responsible for the altera-
tion of NPM1 mutant localization is currently unknown. 
Similar to pharicin B [32], oridonin enhances ATRA-  
induced cell differentiation in ATRA-sensitive NB4 and 
ATRA-resistant NB4-R1 cell lines [61], together with sta-
bilization of RAR, which might be dependent on the 
mildly increased ROS and the subsequent activation of 
NF-B [62]. Besides AML, Guo et al. [63] investigated the 
potential effects of oridonin on Philadelphia chromo-
some-positive acute lymphoblastic leukemia (Ph+ ALL), 
which is triggered by constitutively activated BCR-ABL 
and Src family tyrosine kinases. They found that oridonin 
inhibits activation of Lyn (one of Src family kinases) and 
ABL and their downstream effectors in the Akt/mamma- 
lian target of rapamycin, Raf/mitogen-activated protein 
kinase kinase/ERK, and signal transducer and activator of 
transcription (STAT) 5 pathways. Oridonin also downreg-
ulates Bcl-2 but upregulates Bax protein, leading to apop-
tosis of Ph+ ALL cell line SUB-B15 cells and primary 
specimens from Ph+ ALL patients. 
Although oridonin appears effective in treating various 
kinds of malignant hematologic cancers, the underlying 
mechanism of oridonin is very complicated and its direct 
target is largely unclear. Similar to bioactive naturally  
occurring products such as eriocalyxin B [64] and adenan-
thin [35,45], oridonin also contains an ,-unsaturated 
ketone in the D-ring, destruction of which abolishes its 
anticancer activity. The ,-unsaturated ketone, as a Mi-
chael acceptor, is an electrophilic center susceptible to nu-
cleophilic attack (Michael addition) by a sulfhydryl group 
of reduced glutathione or cysteine residues in proteins, 
leading to adducts at the -position. Thus, alkylation of cru-
cial cysteine residues can result in a loss of function or acti-
vation of the target proteins. As mentioned above, oridonin 
can directly bind cleaved AML1-ETO at Cys347 [58] and 
TrxR [57,65]. TrxRs are essential proteins for regulating 
cellular redox balance and mitigating the damage caused 
by ROS. Inactivation of TrxR is a strategy to treat cancer 
through increasing the intracellular ROS level. In fact, a 
series of investigations have demonstrated that oridon-
in-induced cell death is associated with increased ROS 
production.  
Dal Piaz et al. [66] recently used a chemical proteomic 
approach to identify the molecular chaperone heat shock 
protein (HSP) 70 1A as an oridonin target in leukemic 
Jurkat cells. In detail, oridonin covalently binds to Cys267 
of HSP70 1A and inhibits its activity. HSP70 is an 
ATP-dependent molecular chaperone that plays a key role 
in refolding misfolded proteins and promoting cell survival 
following stress. The chaperone is marginally expressed in 
nontransformed cells, but is greatly elevated in cancer 
cells. Silencing of Hsp70 is cytotoxic to tumor but not to 
normal cells, thus suggesting a mechanism of action for the 
diterpene consistent with its the multiple biological activi-
ties. HSP70 inhibition by oridonin might indeed result in 
impairment of some host proteins, thus affecting several 
molecular pathways. In particular, HSP70 inhibition could 
account for the effects of oridonin on the activity of mito-
gen-activated protein kinases, Akt, BAX, NF-B and 
caspases, since the functionality of these proteins depends 
on HSP70. Of note, Ye et al. [67] reported that vibsanin B, 
a novel macrocyclic diterpenoid isolated from Viburnum 
odoratissimum Ker-Gawl preferentially binds to HSP90 
to inhibit interstitial leukocyte migration, thus ameliorating 
experimental autoimmune encephalomyelitis in mice.  
Notably, leukemia cells resistant to chemothera-
py-induced apoptosis have been found to be sensitive to 
oridonin. As an example, compared with HL60 cells, K562 
and K562/ADR cells were resistant to apoptosis stimulated 
by Ara-C and VP-16, but were sensitive to the effects of 
oridonin. Mechanistic investigations revealed that oridonin 
upregulated BIM-S by diminishing the expression of 
miR-17 and miR-20a, leading to mitochondria-dependent  
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apoptosis. In contrast, neither Ara-C nor VP-16 can reduce 
miR-17 and miR-20a expression or trigger BIM-S-    
mediated apoptosis. Notably, silencing miR-17 or miR-20a 
expression by treatment with microRNA inhibitors or 
oridonin restored sensitivity of K562 cells to VP-16. The 
synergistic effects of oridonin and VP-16 were documented 
in cultured cells as well as mouse tumor xenograft  
assays [68].  
3  Gambogic acid 
Gambogic acid (GA) is a natural compound derived from 
the Chinese herb gamboges, which has been approved by 
the Chinese FDA for the treatment of different cancers in 
clinical trials [69]. Most recently, Liu’s group reported that 
GA overcomes the drug-resistance of hematological ma-
lignancies, including CML with imatinib resistance and 
diffuse large B-cell lymphoma (DLBCL) resistant to 
R-CHOP (rituximab combined with cytoxan, hydroxyrubi-
cin, oncovin, and prednisone). It is well known that the 
BCR-ABL T315I mutation is the predominant cause of 
resistance of CML cells to imatinib [70]. The emergence of 
imatinib resistance in patients with CML les to the search 
for novel approaches for its treatment. Liu’s group [71] has 
investigated the antineoplastic effects of GA in CML cell 
lines, mononuclear cells from CML patients and in 
imatinib-resistant xenograft murine models. The results 
indicated that GA induces apoptosis together with cell pro-
liferation inhibition in CML cells, including those cells 
harboring the BCR-ABL-T315I mutation, and primary 
mononuclear cells from CML patients resistant to imatinib. 
It also inhibits the growth of imatinib-resistant BCR-ABL- 
T315I-carrying CML cell xenografts in nude mice. 
DLBCL is an aggressive form of NHL. Resistance    
to the R-CHOP therapy regimen poses a great challenge  
to improving the survival of patients with DLBCL, espe-
cially those with activated B-cell-like DLBCL (ABC- 
DLBCL) [72]. Therefore it is urgent to search for novel 
agents for the treatment of DLBCL. The Liu group [73] 
investigated the effect of GA on cell survival and apoptosis 
in DLBCL cells including both germinal center B cell 
(GCB-)- and ABC-DLBCL cells. The results collectively 
demonstrated that GA has a significant effect against the 
GCB and ABC subtypes of DLBCL cells both in vitro and 
in vivo. The research provided the first demonstration that 
GA may have clinical benefit in patients with DLBCL, 
particularly in patients with ABC subtypes DLBCL. 
Several potential molecular targets of GA have been re-
ported, including binding to the transferrin receptor and 
suppressing the NF-B signaling pathway [74], as well as 
inhibiting vascular endothelial growth factor receptor    
2 [75]. However, its molecular targets have not been thor-
oughly studied. Liu’s group [76] reported that GA inhibits 
tumor proteasome activity, with potency comparable to 
bortezomib, the first proteasome inhibitor approved for the 
treatment of multiple myeloma, but with less toxicity. 
Their results showed that GA gains the proteasome-   
inhibitory function after being metabolized by intracellular 
CYP2E1, that GA induced proteasome inhibition is a pre-
requisite for its cytotoxicity and anticancer action without 
off-target effects, and that the expression of the CYP2E1 
gene is very high in tumor tissues but low in many normal 
tissues, and thus GA can produce tissue-specific pro-
teasome inhibition and tumor-specific toxicity (Figure 2). 
Further, they showed that GA-induced proteasome inhibi-
tion and caspase activation are required for GA-induced 
BCR-ABL downregulation and cell apoptosis [71]. Judg-
ing by present reports, most current studies are mainly fo-
cused on finding tyrosine kinase inhibitors to either down-
regulate BCR-ABL transcription or inhibit its tyrosine ki-
nase activity. Here, the Liu group proposes an alternative 
strategy to enhance proteasome inhibition-induced 
BCR-ABL downregulation by activating the caspase sys-
tem. Caspase-dependent BCR- ABL cleavage is effective 
both in KBM5-T315I cells and in the cancer cells from 
imatinib-resistant patients with CML, indicating that this 
strategy has a great promise in overcoming imatinib re-
sistance. 
4  Wogonin and wogonoside 
Huang-Qin (Scutellaria baicalensis Georgi), one of the 50 
fundamental herbs used in traditional Chinese medicine, is 
rich in flavonoids including wogonin (5,7-dihydroxy-8-  
 
 
Figure 2  A schematic illustration of the mechanism for gambogic acid 
to induce cytotoxicity of cancer cells [76,77].  
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methoxy-2-phenyl-4H-chromen-4-one) [78–80]. In fact, 
these naturally-derived biologically active polyphenolic 
compounds are widely distributed in plants and relatively 
common in human diets. In the past decades, a series of in 
vitro and in vivo investigations showed that several struc-
turally related flavonoids such as wogonin, luteolin, nobi-
letin and baicalein have multiple biological effects includ-
ing anti-oxidant, anti-inflammatory, anti-viral, neuropro-
tective, anxiolytic, and anti-cancer activities [81–83]. Here 
we focused on the potential anti-leukemia effects of 
wogonin. It was shown that wogonin potently induces 
apoptotic cell death in leukemic HL-60 cells by increasing 
the expression of pro-apoptotic Bax protein and decreasing 
that of the anti-apoptotic myeloid cell leukemia 1 (Mcl-1) 
protein [84] and inhibiting the expression of human te-
lomerase reverse transcriptase, telomerase-associated pro-
tein 1 and Myc mRNA, thereby down-regulating telomer-
ase activity [85]. Recently, wogonin was also reported to 
induce the expression of certain members of the endoplas-
mic reticulum (ER) stress pathway and the activation of 
multiple branches of ER stress transducers, which are pos-
sibly mediated by the inhibition of the phosphoinositide 
3-kinase/Akt signaling pathway [86]. Wogonin was also 
shown to induce cell cycle arrest at the G2/M phase and 
apoptosis of human monocytic leukemia cell line THP-1 
but not that of the normal human fetal lung diploid cell line 
Tokyo Metropolitan Institute of Gerontology (TIG)-1 [87]. 
The following studies demonstrated that wogonin has al-
most no toxicity on T lymphocytes from healthy donors 
but that it induces apoptosis in malignant T cells in vitro 
and suppresses growth of human T-cell leukemia xeno-
grafts in vivo [88]. Mechanistically, wogonin induces pro-
longed activation of phospholipase C1 via H2O2 signaling, 
which leads to cytosolic Ca2+ overload and thus disruption 
of the mitochondrial membrane in malignant but not nor-
mal T cells [88]. Furthermore, wogonin and the structural-
ly related natural flavones apigenin, chrysin and luteolin, 
bind directly to cyclin-dependent kinase 9 (CDK9) pre-
sumably to the ATP-binding pocket, and block phosphory-
lation of the carboxy-terminal domain of RNA polymerase 
II, leading to reduced RNA synthesis and subsequently 
rapid downregulation of the short-lived Mcl-1. Further-
more, wogonin preferentially inhibits CDK9 in malignant 
lymphocytes compared with normal lymphocytes [89,90]. 
More recently, an in vivo study with intraperitoneal injec-
tion of murine leukemia WEHI-3 cells into normal 
BALB/c mice demonstrated that wogonin increases the 
survival rate and the body weight of leukemic mice by 
increasing the populations of T- and B-cells [91]. More 
surprisingly, wogonin displayed little apoptosis-inducing 
effect on human promyelocytic leukemia cell line NB4 
cells, but continuous treatment of wogonin efficiently in-
duces NB4 cells to undergo differentiation [92]. 
Flavonoid aglycones, which undergo rapid and exten-
sive metabolism after either oral or intravenous admin-
istration, enter the bloodstream in the form of glucuronide 
or sulfate conjugates. Very little unchanged aglycone can 
be found in the plasma, although there are high levels of 
glucuronic acid conjugates. Glucuronidation is thought to 
affect the biological activity of aglycones by altering the 
physicochemical properties of flavonoids, in what is con-
sidered a detoxification process [93]. Wogonin undergoes 
rapid metabolism and enters the bloodstream mainly in the 
form of the glucuronide wogonoside (Figure 1). As a me-
tabolite of wogonin, wogonoside can also be derived from 
Scutellaria baicalensis Georgi. This wogonin derivative 
has been known to possess anti-inflammatory activity [94] 
and to inhibit lipopolysaccharide-induced angiogenesis  
in vitro and in vivo via toll-like receptor 4 signal transduc-
tion [95]. Wogonoside appears to have less toxicity to 
AML cells than wogonin does in vitro, in spite of no obvi-
ous difference in terms of acute in vivo toxicity. Therefore, 
it is interesting to investigate the potential effects of wog-
onoside on leukemic cells. Indeed, wogonoside exerts an in 
vitro antiproliferative activity in the AML cell lines U937, 
HL-60, and primary AML cells, and it inhibits the prolifer-
ation of U937 xenografts and prolongs survival in 
AML-bearing mice in vivo. Wogonoside-induced cell cycle 
arrest is associated with the downregulation of cyclin D1 
and CDK4, and it also induces the differentiation of AML 
cell lines and primary AML cells [96].  
Phospholipid scramblase 1 (PLSCR1) is a calci-
um-binding, multiply palmitoylated type II endofacial 
plasma membrane protein, which is localized in either the 
cell membrane or nucleus depending on its palmitoylated 
state. In the nuclei, the unpalmitoylated PLSCR1 protein 
can bind to genomic DNA. Early research showed that 
PLSCR1 contributes to the trans-bilayer movement of 
phospholipids, and the following studies revealed that 
PLSCR1 expression can be induced by some cytokines 
such as interferon, epidermal growth factor, and leukemic 
cell differentiation-inducing agents such as ATRA and 
phorbol 12-myristate 13-acetate [97,98]. Moreover, the 
induction of PLSCR1 transcription depends upon sequen-
tial activation of protein kinase C delta (PKC), c-Jun 
N-terminal kinases, and the phosphorylation of STAT1 at 
Ser-727 [99]. PLSCR1 was also shown to interact with 
several protein kinases including c-Abl, c-Src, PKC   
and onzin, suggesting a role of PLSCR1 in cell signal-  
ing [100–102]. Employinging an inducible PLSCR1- 
expressing myeloid leukemia U937 cell line, we showed 
that inducible PLSCR1 expression arrests the proliferation 
at the G1 phase and induces granulocyte-like differentiation 
with increased sensitivity to etoposide-induced apoptosis 
of the genetically engineered cells [103]. Of great interest 
is the fact that PLSCR1 expression can also be induced 
during wogonin and wogonoside-induced differentiation of 
AML-derived cell lines via dramatically increased PKC 
phosphorylation at Ser643 [92,96]. Moreover, p21waf1/cip1 
expression in wogonoside-treated cells increases at 48 h 
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post-treatment, while conversely, the levels of c-Myc pro-
tein decrease upon exposure to wogonoside. The silencing 
of PLSCR1 by its sequence-specific siRNA blocks the 
wogonoside-induced increase in p21waf1/cip1 and decrease in 
c-Myc [96]. PLSCR1 was found inside the nuclei in U937 
and HL-60 cells after treatment with wogonoside. It spe-
cifically binds to a segment of the 5′-promoter of inositol 
1,4,5-trisphosphate receptor 1 (IP3R1: 101GTAACCATG- 
TGGA89), enhancing the transcription of this gene [104]. 
IP3R1 is known to play a key role in IP3-mediated mobi-
lization of intracellular Ca2+ stores from the ER in a variety 
of cells and tissues, and it is also essential for cell growth 
and differentiation [105,106]. Wogonoside promotes nu-
clear PLSCR1 binding to the transcriptional activation 
domain of IP3R1 and increases IP3R1 protein expression. 
SiRNA against PLSCR1 effectively blocked the increased 
expression of IP3R1 when cells were cultured with wogo-
noside. Wogonoside thus appears to augment PLSCR1 
expression at the transcriptional level and promotes its 
localization in the nucleus and its binding to the IP3R1 
promoter, thus influencing the expression of this receptor. 
Cumulatively, wogonin and its metabolite wogonoside 
appear to be of therapeutic potential in leukemia, and their 
clinical effectiveness deserves to be further investigated. 
5  Conclusions 
Numerous naturally occurring small molecules from the 
plant kingdom have interesting properties against cancers, 
especially hematological malignancies. They might target 
different molecular regulatory pathways to interfere with 
the proliferation, differentiation, and death of hematologi-
cal malignant cells or malignant hematopoietic 
stem/progenitor cells [8]. To date, the Dictionary of Natu-
ral Products has recorded approximately 200000 plant 
secondary metabolites, with about 170,000 unique struc-
tures. Approximately 15% of the drug interventions in the 
ClinicalTrials.gov database are plant-related, while about 
60% of these drugs are sourced from plants [107]. In spite 
of these successes, the vast majority of plant species re-
main to be systematically investigated in drug discovery 
campaigns. In particular, bioactive compounds from herbs 
that are used in our traditional medicine still need to be 
more thoroughly explored, and the constant development 
of high-throughput functional assays and phenotypic 
screens in the omics era provides new opportunities for 
revival of interest in natural products for drug discovery.  
Besides drug discovery, the use of bioactive small mol-
ecules will help to decipher and control life’s processes, 
thus promoting our understanding of the molecular mecha-
nisms of normal and abnormal cellular activities. Based on 
this, the term “chemical biology” has rightly been given to 
this thriving area at the interface of chemistry and biomed-
icine. In spite of its definition, the core element of chemi-
cal biology is the use of exogenous chemistry (chemicals) 
to interrogate, modify, and manipulate biological systems 
at the cellular and organismal level in a highly controlled 
manner. From this view, chemicals offer opportunities 
usually not shared by classical genetic methods. On one 
hand, chemicals act rapidly such that the consequences of 
treatment with them can often be recorded after only 
minutes or seconds. Their effects are tunable and their in-
fluence is reversible, providing temporal control of protein 
function because the small molecules usually can be 
washed out or are metabolized. On the other hand, small 
bioactive molecules allow the targeting of proteins whose 
mutations, knock-out, or knock-down would be lethal. 
Moreover, chemicals can be used at any time point chosen 
for application. It is therefore crucial to identify and con-
firm the targets of bioactive small-molecules. In conclu-
sion, scientists from biological, medicinal and chemical 
fields should come together to find more active compounds 
against hematological malignancies and to identify their 
targets. 
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